BR112012017696A2 - Purificação de fatores de coagulação de sangue - Google Patents

Purificação de fatores de coagulação de sangue

Info

Publication number
BR112012017696A2
BR112012017696A2 BR112012017696A BR112012017696A BR112012017696A2 BR 112012017696 A2 BR112012017696 A2 BR 112012017696A2 BR 112012017696 A BR112012017696 A BR 112012017696A BR 112012017696 A BR112012017696 A BR 112012017696A BR 112012017696 A2 BR112012017696 A2 BR 112012017696A2
Authority
BR
Brazil
Prior art keywords
factor
purification
gamma carboxyglutamic
sample
factors
Prior art date
Application number
BR112012017696A
Other languages
English (en)
Inventor
Rose Bjelke Jais
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of BR112012017696A2 publication Critical patent/BR112012017696A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PURIFICAÇÃO DE FATORES DE COAGULAÇÃO DE SANGUE. A presente invenção refere-se à purificação de fatores de coagulação de sangue dependentes de vitamina K, tal como Fator IX (FIX). Em particular, a invenção provê um método para a purificação de Fator IX tendo um teor desejado de ácido gama carboxiglutâmico de uma amostra compreendendo uma mistura das espécies do dito Fator IX tendo diferentes teores de ácido gama carboxiglutâmico, o dito método compreendendo as etapas de: (a) carregamento da dita amostra de Fator IX sobre um material de cromatografia por imunoafinidade acoplada a uma porção de ligação para ácido gama carboxiglutâmico; (b) eluição do dito Fator IX; e (c) seleção de uma fração obtida a partir da dita eluição em que os polipeptídeos na fração têm o teor desejado de ácidos gama carboxiglutâmicos; caracterizado pelo fato de que a concentração total de Fator IX dentro da dita amostra excede a capacidade de ligação do material de cromatografia por imunoafinidade.
BR112012017696A 2010-01-18 2011-01-18 Purificação de fatores de coagulação de sangue BR112012017696A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10150980 2010-01-18
US29701110P 2010-01-21 2010-01-21
PCT/EP2011/050594 WO2011086197A1 (en) 2010-01-18 2011-01-18 Purification of blood coagulation factors

Publications (1)

Publication Number Publication Date
BR112012017696A2 true BR112012017696A2 (pt) 2017-10-03

Family

ID=42173365

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012017696A BR112012017696A2 (pt) 2010-01-18 2011-01-18 Purificação de fatores de coagulação de sangue

Country Status (8)

Country Link
US (1) US9896677B2 (pt)
EP (1) EP2526115B1 (pt)
JP (1) JP6250931B2 (pt)
KR (1) KR20120118028A (pt)
CN (1) CN102939299B (pt)
BR (1) BR112012017696A2 (pt)
RU (1) RU2012133474A (pt)
WO (1) WO2011086197A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011086197A1 (en) * 2010-01-18 2011-07-21 Novo Nordisk Health Care Ag Purification of blood coagulation factors
CN103539852B (zh) * 2012-07-12 2015-08-12 上海泰龙生物医药科技有限公司 一种从细胞培养液中分离纯化重组人凝血八因子的方法
US9708404B2 (en) 2012-12-21 2017-07-18 Seattle Genetics, Inc. Anti-NTB-A antibodies and related compositions and methods
US10643423B2 (en) 2016-09-23 2020-05-05 Sg Gaming, Inc. System and digital table for binding a mobile device to a position at the table for transactions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258938B1 (en) 1983-10-28 2001-07-10 Ne Medical Center Hospital, Inc. Method for the purification and isolation of blood clotting proteins using conformation specific antibodies
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
FR2632309B1 (fr) 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
SG48282A1 (en) 1991-03-01 1998-04-17 Centeon Llc Preparation of factor ix
IT1262899B (it) 1992-03-27 1996-07-22 Sclavo Spa Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umano
DE4406515C1 (de) 1994-02-28 1995-10-19 Immuno Ag Verfahren zur Isolierung und Reinigung Vitamin K-abhängiger Proteine
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
SE0000675D0 (sv) 2000-03-02 2000-03-02 Protease Ab Monoclonal antibodies
AU2004221758B2 (en) 2003-03-18 2010-07-22 Novo Nordisk Health Care Ag Method for the production of GLA-residue containing serine proteases
EP1831242B1 (en) 2004-12-23 2012-09-26 Novo Nordisk Health Care AG Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest
US8647868B2 (en) 2005-12-02 2014-02-11 Wake Forest University Health Sciences Compositions and methods for increasing production of recombinant gamma-carboxylated proteins
EP2125866B1 (en) 2007-02-28 2013-05-22 Baxter International Inc. Method for the purification of recombinant blood coagulation factor ix enriched in sulfated and/or phosphorylated molecules
KR101821143B1 (ko) 2008-12-02 2018-01-23 노보 노르디스크 헬스 케어 악티엔게젤샤프트 폴리펩티드 정제
WO2011086197A1 (en) * 2010-01-18 2011-07-21 Novo Nordisk Health Care Ag Purification of blood coagulation factors

Also Published As

Publication number Publication date
CN102939299A (zh) 2013-02-20
KR20120118028A (ko) 2012-10-25
EP2526115A1 (en) 2012-11-28
US9896677B2 (en) 2018-02-20
WO2011086197A1 (en) 2011-07-21
CN102939299B (zh) 2016-04-20
US20130034896A1 (en) 2013-02-07
JP6250931B2 (ja) 2017-12-20
EP2526115B1 (en) 2018-08-01
JP2013517259A (ja) 2013-05-16
RU2012133474A (ru) 2014-02-27

Similar Documents

Publication Publication Date Title
Mayourian et al. Exosomal microRNA-21-5p mediates mesenchymal stem cell paracrine effects on human cardiac tissue contractility
Lim et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23
BR112019006706A2 (pt) métodos melhorados para avaliar o estado de gfap em amostras de paciente
CL2017002650A1 (es) Compuestos novedosos
ECSP11010831A (es) Compuestos orgánicos para la cicatrización de heridas
BR112012017696A2 (pt) Purificação de fatores de coagulação de sangue
BR112013028779B8 (pt) proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, e, uso de uma composição
WO2010041913A3 (ko) Grs 단백질 또는 이의 단편의 신규한 용도
WO2013190075A3 (en) Specific biomarkers for hepatocellular carcinoma (hcc)
PE20110400A1 (es) Composiciones mejoradas de celulas y metodos para preparar las mismas
BR112015015341A2 (pt) composições para permeabilização de células sanguíneas fixadas e usos das mesmas
BR112012026953A8 (pt) Composto, uso de um composto, composição farmacêutica, e processo para preparar uma composição farmacêutica
BR112015009376A2 (pt) ácidos indaniloxidihidrobenzofuranilacéticos
BR112018067597A2 (pt) célula progenitora de fígado adulto, população celular, material biológico, composição, método para avaliar a eficácia, o metabolismo, a estabilidade e/ou a toxicidade de um ou mais compostos, uso da célula ou população celular e kit
BRPI0509182A (pt) co-cristais de gossipol e uso dos mesmos
EP2813854A4 (en) HEMOLYSIS REAGENT COMPOSITION FOR QUANTITATIVE ANALYSIS OF HEMOGLOBIN A1C USING AN ENZYMATIC PROCESS
BRPI0920259A8 (pt) Molécula de fator sanguíneo modificado, composição farmacêutica, e, métodos para preparar uma molécula de fator sanguíneo modificado e para tratar um indivíduo sofrendo de um distúrbio de coagulação sanguínea
BR112013032714A2 (pt) curativo para ferida biorreabsorvível
MX351846B (es) Preparacion de suero.
BR112021012065A2 (pt) Anticorpo biespecífico que se liga a fixa e fx e catalisa a ativação de fx mediada por fixa; método; anticorpo anti-fixa; anticorpo anti-fx; ácido nucleico isolado; célula hospedeira in vitro; população de células hospedeiras in vitro; kit para produção de um anticorpo biespecífico; método de produção de um anticorpo biespecífico; composição; método para controlar o sangramento em um paciente com hemofilia a; uso de um anticorpo biespecífico; método, composição para uso ou uso; e método para reduzir o desenvolvimento de anticorpos antifármacos inibidores em um paciente com hemofilia a em tratamento com um polipeptídeo que substitui a atividade de fviiia
BR112018000841A2 (pt) agente estimulante de receptor 5-hidroxitriptamina1b para uso como um promotor de auto-renovação e/ou diferenciação de células satélites
CR20130106A (es) Nuevos moduladores de trpv3
WO2012122334A3 (en) Procollagen carboxy-terminal propeptides as a target and treatment for angiogenesis related diseases
BR112014026351A2 (pt) microesferas de cristal e processo para a produção das mesmas
BR112012015449A2 (pt) suspensão de monoidrato de calcipotriol, monoidrato de calcipotriol, processo para preparar nanocristais de monoidrato de calcipotriol, e, composição farmacêutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B25H Request for change of headquarter rejected

Owner name: NOVO NORDISK HEALTH CARE AG (CH)

B350 Update of information on the portal [chapter 15.35 patent gazette]